Last reviewed · How we verify
salmeterol 50mcg
At a glance
| Generic name | salmeterol 50mcg |
|---|---|
| Also known as | Fluticasone Propionate/Salmeterol 500/50mcg combination, Fluticasone Propionate 500mcg |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Mechanism(s) of Airflow Limitation During Exacerbation of Asthma (PHASE4)
- New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD) (EARLY_PHASE1)
- Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (PHASE4)
- Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study) (PHASE4)
- A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise (PHASE4)
- A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma (PHASE3)
- A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- salmeterol 50mcg CI brief — competitive landscape report
- salmeterol 50mcg updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI